sparsentan
021IGAN17001
Phase 3 small_molecule active
Quick answer
sparsentan for Immunoglobulin A Nephropathy is a Phase 3 program (small_molecule) at Travere Therapeutics with 3 ClinicalTrials.gov record(s).
Program details
- Company
- Travere Therapeutics
- Indication
- Immunoglobulin A Nephropathy
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active